Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Cannabinoids, including the endogenous ligand arachidonyl ethanolamide (anandamide), elicit not only neurobehavioral but also cardiovascular effects. Two cannabinoid receptors, CB1 and CB2, have been cloned, and studies with the selective CB1 receptor antagonist SR141716A have implicated peripherally located CB1 receptors in the hypotensive action of cannabinoids. In rat mesenteric arteries, anandamide-induced vasodilation is inhibited by SR141716A, but other potent CB1 receptor agonists, such as HU-210, do not cause vasodilation, which implicates an as-yet-unidentified receptor in this effect. Here we show that “abnormal cannabidiol” (Abn-cbd) is a neurobehaviorally inactive cannabinoid that does not bind to CB1 receptors, yet causes SR141716A-sensitive hypotension and mesenteric vasodilation in wild-type mice and in mice lacking CB1 receptors or both CB1 and CB2 receptors. Hypotension by Abn-cbd is also inhibited by cannabidiol (20 μg/g), which does not influence anandamide- or HU-210-induced hypotension. In the rat mesenteric arterial bed, Abn-cbd-induced vasodilation is unaffected by blockade of endothelial NO synthase, cyclooxygenase, or capsaicin receptors, but it is abolished by endothelial denudation. Mesenteric vasodilation by Abn-cbd, but not by acetylcholine, sodium nitroprusside, or capsaicine, is blocked by SR141716A (1 μM) or by cannabidiol (10 μM). Abn-cbd-induced vasodilation is also blocked in the presence of charybdotoxin (100 nM) plus apamin (100 nM), a combination of K + -channel toxins reported to block the release of an endothelium-derived hyperpolarizing factor (EDHF). These findings suggest that Abn-cbd and cannabidiol are a selective agonist and antagonist, respectively, of an as-yet-unidentified endothelial receptor for anandamide, activation of which elicits NO-independent mesenteric vasodilation, possibly by means of the release of EDHF.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor
Devane, W. A., Hanuš, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., & Mechoulam, R. (1992) · Science · doi:10.1126/science.1470919 · Cited by 5,633
Molecular characterization of a peripheral receptor for cannabinoids
Munro, S., Thomas, K. L., & Abu-Shaar, M. (1993) · Nature · doi:10.1038/365061a0 · Cited by 5,092
Structure of a cannabinoid receptor and functional expression of the cloned cDNA
Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C., & Bonner, T. I. (1990) · Nature · doi:10.1038/346561a0 · Cited by 5,011
Self-citationLedent, C., Valverde, O., Cossu, G., Petitet, F., Aubert, J.-F., Beslot, F., Böhme, G. A., Imperato, A., Pedrazzini, T., Roques, B. P., et al. (1999) · Science · doi:10.1126/science.283.5400.401 · Cited by 3,614
Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide
Zygmunt, P. M., Petersson, J., Andersson, D. A., Chuang, H.-H., Sørgård, M., Di Marzo, V., Julius, D., & Högestätt, E. D. (1999) · Nature · doi:10.1038/22761 · Cited by 2,142
SR141716A, a potent and selective antagonist of the brain cannabinoid receptor
Rinaldi-Carmona, M., Barth, F., Héaulme, M., Shire, D., Calandra, B., Congy, C., Martinez, S., Maruani, J., Néliat, G., Caput, D., et al. (1994) · FEBS Letters · doi:10.1016/0014-5793(94)00773-x · Cited by 1,757
Formation and inactivation of endogenous cannabinoid anandamide in central neurons
Di Marzo, V., Fontana, A., Cadas, H., Schinelli, S., Cimino, G., Schwartz, J.-C., & Piomelli, D. (1994) · Nature · doi:10.1038/372686a0 · Cited by 1,587
Identification of Epoxyeicosatrienoic Acids as Endothelium-Derived Hyperpolarizing Factors
Campbell, W. B., Gebremedhin, D., Pratt, P. F., & Harder, D. R. (1996) · Circulation Research · doi:10.1161/01.res.78.3.415 · Cited by 1,221
Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice
Zimmer, A., Zimmer, A. M., Hohmann, A. G., Herkenham, M., & Bonner, T. I. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.10.5780 · Cited by 1,064
Self-citationK+ is an endothelium-derived hyperpolarizing factor in rat arteries
Edwards, G., Dora, K. A., Gardener, M. J., Garland, C. J., & Weston, A. H. (1998) · Nature · doi:10.1038/24388 · Cited by 1,058
Cited by
International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors
Howlett, A. C., Barth, F., Bonner, T. I., Cabral, G., Casellas, P., Devane, W. A., Felder, C. C., Herkenham, M., Mackie, K., Martin, B. R., et al. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.2.161 · Cited by 2,819
Self-citationThe Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077
Self-citationThe molecular logic of endocannabinoid signalling
Piomelli, D. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1247 · Cited by 1,957
“A novel cannabinoid site has also been identified in the vascular endotheliu”
BackgroundPertwee, R. G., Howlett, A. C., Abood, M. E., Alexander, S. P. H., Di Marzo, V., Elphick, M. R., Greasley, P. J., Hansen, H. S., Kunos, G., Mackie, K., et al. (2010) · Pharmacological Reviews · doi:10.1124/pr.110.003004 · Cited by 1,605
Self-citationRole of Endogenous Cannabinoids in Synaptic Signaling
FREUND, T. F., KATONA, I., & PIOMELLI, D. (2003) · Physiological Reviews · doi:10.1152/physrev.00004.2003 · Cited by 1,574
The orphan receptor GPR55 is a novel cannabinoid receptor
Ryberg, E., Larsson, N., Sjögren, S., Hjorth, S., Hermansson, N., Leonova, J., Elebring, T., Nilsson, K., Drmota, T., & Greasley, P. J. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707460 · Cited by 1,568
“WIN55,212-2 has been shown to be without effect at novel CB receptors in the vasculature while abnormal cannabidiol behaves as an agonist and cannabidiol is an antagonist (Jarai et al., 1999).”
BackgroundInfluentialLeptin-regulated endocannabinoids are involved in maintaining food intake
Di Marzo, V., Goparaju, S. K., Wang, L., Liu, J., Bátkai, S., Járai, Z., Fezza, F., Miura, G. I., Palmiter, R. D., Sugiura, T., et al. (2001) · Nature · doi:10.1038/35071088 · Cited by 1,559
Self-citationCravatt, B. F., Demarest, K., Patricelli, M. P., Bracey, M. H., Giang, D. K., Martin, B. R., & Lichtman, A. H. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.161191698 · Cited by 1,310
Self-citationEndocannabinoid Signaling in the Brain
Wilson, R. I., & Nicoll, R. A. (2002) · Science · doi:10.1126/science.1063545 · Cited by 1,260
Anandamide and arachidonic acid use epoxyeicosatrienoic acids to activate TRPV4 channels
Watanabe, H., Vriens, J., Prenen, J., Droogmans, G., Voets, T., & Nilius, B. (2003) · Nature · doi:10.1038/nature01807 · Cited by 1,027
Triggering Myocardial Infarction by Marijuana
Mittleman, M. A., Lewis, R. A., Maclure, M., Sherwood, J. B., & Muller, J. E. (2001) · Circulation · doi:10.1161/01.cir.103.23.2805 · Cited by 767
Nonpsychotropic Cannabinoid Receptors Regulate Microglial Cell Migration
Walter, L., Franklin, A., Witting, A., Wade, C., Xie, Y., Kunos, G., Mackie, K., & Stella, N. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-04-01398.2003 · Cited by 665
Self-citationOverton, H. A., Babbs, A. J., Doel, S. M., Fyfe, M. C. T., Gardner, L. S., Griffin, G., Jackson, H. C., Procter, M. J., Rasamison, C. M., Tang-Christensen, M., et al. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.02.004 · Cited by 655
Cannabinoid physiology and pharmacology: 30 years of progress
Howlett, A. C., Breivogel, C. S., Childers, S. R., Deadwyler, S. A., Hampson, R. E., & Porrino, L. J. (2004) · Neuropharmacology · doi:10.1016/j.neuropharm.2004.07.030 · Cited by 608
“…function have elucidated a novel endothelial cell G-protein-coupled receptor that regulates vasorelaxation in response to anandamide, methanandamide and abnormal cannabidiol, but not cannabinoid or aminoalkylindole compounds (Jarai et al., 1999; Wagner et al., 1999; Mukhopadhyay et al., 2002).”
BackgroundPharmacological Actions of Cannabinoids
Pertwee, R. G. (2005) · Handbook of Experimental Pharmacology · doi:10.1007/3-540-26573-2_1 · Cited by 597
Molecular Targets of Cannabidiol in Neurological Disorders
Ibeas Bih, C., Chen, T., Nunn, A. V. W., Bazelot, M., Dallas, M., & Whalley, B. J. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0377-3 · Cited by 578
Cannabinoid receptors and their ligands
Pertwee, R. G., & Ross, R. A. (2002) · Prostaglandins, Leukotrienes and Essential Fatty Acids (PLEFA) · doi:10.1054/plef.2001.0341 · Cited by 561
Presynaptic Specificity of Endocannabinoid Signaling in the Hippocampus
Wilson, R. I., Kunos, G., & Nicoll, R. A. (2001) · Neuron · doi:10.1016/s0896-6273(01)00372-5 · Cited by 544
Self-citationEvidence for a New G Protein-Coupled Cannabinoid Receptor in Mouse Brain
Breivogel, C. S., Griffin, G., Di Marzo, V., & Martin, B. R. (2001) · Molecular Pharmacology · doi:10.1124/mol.60.1.155 · Cited by 541
Self-citationHowlett, A. C. (2002) · Prostaglandins & Other Lipid Mediators · doi:10.1016/s0090-6980(02)00060-6 · Cited by 535
Cannabinoid and cannabinoid‐like receptors in microglia, astrocytes, and astrocytomas
Stella, N. (2010) · Glia · doi:10.1002/glia.20983 · Cited by 527
Cannabidiol: An Overview of Some Pharmacological Aspects
Mechoulam, R., Parker, L. A., & Gallily, R. (2002) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.2002.tb05998.x · Cited by 508
TRPV4 calcium entry channel: a paradigm for gating diversity
Nilius, B., Vriens, J., Prenen, J., Droogmans, G., & Voets, T. (2004) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00365.2003 · Cited by 491
Endocannabinoid system and stress and anxiety responses
VIVEROS, M., MARCO, E., & FILE, S. (2005) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2005.01.029 · Cited by 485
The Endocannabinoid System and Pain
Guindon, J., & Hohmann, A. (2009) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152709789824660 · Cited by 476
The endocannabinoid system: a general view and latest additions
Petrocellis, L. D., Cascio, M. G., & Marzo, V. D. (2004) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705666 · Cited by 475
Antifibrogenic role of the cannabinoid receptor CB2 in the liver
Julien, B., Grenard, P., Teixeira-Clerc, F., Van Nhieu, J. T., Li, L., Karsak, M., Zimmer, A., Mallat, A., & Lotersztajn, S. (2005) · Gastroenterology · doi:10.1053/j.gastro.2004.12.050 · Cited by 470
Self-citationLigresti, A., De Petrocellis, L., & Di Marzo, V. (2016) · Physiological Reviews · doi:10.1152/physrev.00002.2016 · Cited by 469
Inverse agonism and neutral antagonism at cannabinoid CB1 receptors
Pertwee, R. G. (2005) · Life Sciences · doi:10.1016/j.lfs.2004.10.025 · Cited by 444
The endocannabinoid system as a target for therapeutic drugs
Piomelli, D., Giuffrida, A., Calignano, A., & Rodrı́guez de Fonseca, F. (2000) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)01482-6 · Cited by 421
Demuth, D. G., & Molleman, A. (2006) · Life Sciences · doi:10.1016/j.lfs.2005.05.055 · Cited by 420
Brown, A. J. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707481 · Cited by 409
Cabral, G. A., & Griffin-Thomas, L. (2009) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399409000957 · Cited by 408
Di Marzo, V., Breivogel, C. S., Tao, Q., Bridgen, D. T., Razdan, R. K., Zimmer, A. M., Zimmer, A., & Martin, B. R. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0752434.x · Cited by 393
Self-citationEvidence for novel cannabinoid receptors
BEGG, M., PACHER, P., BATKAI, S., OSEIHYIAMAN, D., OFFERTALER, L., MO, F., LIU, J., & KUNOS, G. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2004.11.005 · Cited by 385
Self-citationBátkai, S., Járai, Z., Wagner, J. A., Goparaju, S. K., Varga, K., Liu, J., Wang, L., Mirshahi, F., Khanolkar, A. D., Makriyannis, A., et al. (2001) · Nature Medicine · doi:10.1038/89953 · Cited by 378
Self-citationDe Petrocellis, L., Bisogno, T., Maccarrone, M., Davis, J. B., Finazzi-Agrò, A., & Di Marzo, V. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008555200 · Cited by 355
The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety
Haller, J., Bakos, N., Szirmay, M., Ledent, C., & Freund, T. F. (2002) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2002.02192.x · Cited by 354
“…was administered to both wild-type and CB1-knockout mice, as it has been shown that some effects of cannabinoids are preserved in CB1knockout mice (Jarai et al., 1999; Zimmer et al., 1999; Di Marzo et al., 2000; Breivogel et al., 2001; HaÂjos et al., 2001), providing evidence for the existence of…”
BackgroundMethodSUGIURA, T., KISHIMOTO, S., OKA, S., & GOKOH, M. (2006) · Progress in Lipid Research · doi:10.1016/j.plipres.2006.03.003 · Cited by 352
The Endocannabinoid System: Drug Targets, Lead Compounds, and Potential Therapeutic Applications
Lambert, D. M., & Fowler, C. J. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm058183t · Cited by 350
In silico patent searching reveals a new cannabinoid receptor
Baker, D., Pryce, G., Davies, W. L., & Hiley, C. R. (2006) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.11.003 · Cited by 348
De Petrocellis, L., Bisogno, T., Davis, J. B., Pertwee, R. G., & Di Marzo, V. (2000) · FEBS Letters · doi:10.1016/s0014-5793(00)02082-2 · Cited by 347
Anandamide Induces Apoptosis in Human Cells via Vanilloid Receptors
Maccarrone, M., Lorenzon, T., Bari, M., Melino, G., & Finazzi-Agrò, A. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m005722200 · Cited by 347
CB2receptors in the brain: role in central immune function
Cabral, G. A., Raborn, E. S., Griffin, L., Dennis, J., & Marciano‐Cabral, F. (2008) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707584 · Cited by 342
Cannabinoids and neuroinflammation
Walter, L., & Stella, N. (2004) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705667 · Cited by 336
Functional CB1 cannabinoid receptors in human vascular endothelial cells
Liu, J., Gao, B., Mirshahi, F., Sanyal, A. J., Khanolkar, A. D., Makriyannis, A., & Kunos, G. (2000) · Biochemical Journal · doi:10.1042/0264-6021:3460835 · Cited by 333
Self-citationMcHugh, D., Hu, S. S., Rimmerman, N., Juknat, A., Vogel, Z., Walker, J. M., & Bradshaw, H. B. (2010) · BMC Neuroscience · doi:10.1186/1471-2202-11-44 · Cited by 323
Endocannabinoids Acting at Cannabinoid-1 Receptors Regulate Cardiovascular Function in Hypertension
Bátkai, S., Pacher, P., Osei-Hyiaman, D., Radaeva, S., Liu, J., Harvey-White, J., Offertáler, L., Mackie, K., Rudd, M. A., Bukoski, R. D., et al. (2004) · Circulation · doi:10.1161/01.cir.0000143230.23252.d2 · Cited by 322
Self-citationCardiovascular System Effects of Marijuana
Jones, R. T. (2002) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.2002.tb06004.x · Cited by 319
The endocannabinoid anandamide is a direct and selective blocker of the background K+ channel TASK-1
Maingret, F. (2001) · The EMBO Journal · doi:10.1093/emboj/20.1.47 · Cited by 313
Direct inhibition of T-type calcium channels by the endogenous cannabinoid anandamide
Chemin, J. (2001) · The EMBO Journal · doi:10.1093/emboj/20.24.7033 · Cited by 299
Inhibition of tumor angiogenesis by cannabinoids
Blázquez, C., Casanova, M. L., Planas, A., Gómez del Pulgar, T., Villanueva, C., Fernández‐Aceñero, M. J., Aragonés, J., Huffman, J. W., Jorcano, J. L., & Guzmán, M. (2003) · The FASEB Journal · doi:10.1096/fj.02-0795fje · Cited by 292
Manzanares, J., Julian, M., & Carrascosa, A. (2006) · Current Neuropharmacology · doi:10.2174/157015906778019527 · Cited by 287
“Two have been cloned, type 1 (CB1) and type 2 (CB2) cannabinoid receptors [100, 108], while the other two, WIN and abnormal-cannabidiol (abn-CBD) receptors (the latter also known as anandamide receptor), have been characterised pharmacologically [8, 31, 51, 71, 107].”
Kozela, E., Pietr, M., Juknat, A., Rimmerman, N., Levy, R., & Vogel, Z. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.069294 · Cited by 286
Haller, J., Varga, B., Ledent, C., Barna, I., & Freund, T. F. (2004) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2004.03293.x · Cited by 284
Tanda, G., & Goldberg, S. R. (2003) · Psychopharmacology · doi:10.1007/s00213-003-1485-z · Cited by 277
Cannabinoid receptors and endocannabinoids: Evidence for new players
Mackie, K., & Stella, N. (2006) · The AAPS Journal · doi:10.1007/bf02854900 · Cited by 275
Neuroprotective and Blood-Retinal Barrier-Preserving Effects of Cannabidiol in Experimental Diabetes
El-Remessy, A. B., Al-Shabrawey, M., Khalifa, Y., Tsai, N.-T., Caldwell, R. B., & Liou, G. I. (2006) · The American Journal of Pathology · doi:10.2353/ajpath.2006.050500 · Cited by 274
Defective Adult Neurogenesis in CB1 Cannabinoid Receptor Knockout Mice
Jin, K., Xie, L., Kim, S. H., Parmentier-Batteur, S., Sun, Y., Mao, X. O., Childs, J., & Greenberg, D. A. (2004) · Molecular Pharmacology · doi:10.1124/mol.66.2.204 · Cited by 273
Endocannabinoid signaling in microglial cells
Stella, N. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.07.037 · Cited by 272
Antitumor Effects of Cannabidiol, a Nonpsychoactive Cannabinoid, on Human Glioma Cell Lines
Massi, P., Vaccani, A., Ceruti, S., Colombo, A., Abbracchio, M. P., & Parolaro, D. (2004) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.061002 · Cited by 271
Ho, W., Barrett, D. A., & Randall, M. D. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.324 · Cited by 259
Melis, M., Perra, S., Muntoni, A. L., Pillolla, G., Lutz, B., Marsicano, G., Di Marzo, V., Gessa, G. L., & Pistis, M. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.3502-04.2004 · Cited by 253
Haller, J., Varga, B., Ledent, C., & Freund, T. F. (2004) · Behavioural Pharmacology · doi:10.1097/01.fbp.0000135704.56422.40 · Cited by 241
Beyond THC and Endocannabinoids
Pacher, P., Kogan, N. M., & Mechoulam, R. (2020) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010818-021441 · Cited by 175
Cannabinoid-Induced Immune Suppression and Modulation of Antigen-Presenting Cells
Klein, T. W., & Cabral, G. A. (2006) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-005-9007-x · Cited by 172
Endocannabinoids limit excessive mast cell maturation and activation in human skin
Sugawara, K., Bíró, T., Tsuruta, D., Tóth, B. I., Kromminga, A., Zákány, N., Zimmer, A., Funk, W., Gibbs, B. F., Zimmer, A., et al. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.11.009 · Cited by 138
Self-citationNicotine and cannabinoids: parallels, contrasts and interactions
VIVEROS, M., MARCO, E., & FILE, S. (2006) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2006.08.002 · Cited by 106
Chapter 4.5 The endocannabinoid system and anxiety responses
Bortolato, M., & Piomelli, D. (2008) · Handbook of Behavioral Neuroscience · doi:10.1016/s1569-7339(07)00014-8 · Cited by 7
Metadata
- Authors
- Járai, Z., Wagner, J. A., Varga, K., Lake, K. D., Compton, D. R., Martin, B. R., Zimmer, A. M., Bonner, T. I., Buckley, N. E., Mezey, E., Razdan, R. K., Zimmer, A., & Kunos, G.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1999-11-23
- Volume
- 96
- Issue
- 24
- Pages
- 14136-14141
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2116169298
- Cited by
- 599
- References
- 41
- FWCI
- 18.78
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.